Trial
NCT03791060
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Novartis Pharmaceuticals
Condition
Necrobiosis Lipoidica Diabeticorum
Intervention
Secukinumab
Why stopped
Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-17